A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy
The main purpose of this study is to measure the safety and efficacy of insulin efsitora alfa (LY3209590) compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.
Inclusion Criteria:
Exclusion Criteria:
Fort Lauderdale, Florida 33312, United States
Hyattsville, Maryland 20782, United States
CABA, Buenos Aires C1060ABN, Argentina
Ciudad Autónoma de Buenos Aire, Buenos Aires 1056, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Air C1405BUB, Argentina
Capital, Córdoba Province X5008HHW, Argentina
Godoy Cruz, Mendoza Province M5501ARP, Argentina
San Miguel de Tucumán, Tucumán Province 4000, Argentina
Kamakura-shi, Kanagawa 247-0056, Japan
Saitama-shi, Saitama 336-0967, Japan
Chuo-ku, Tokyo 103-0002, Japan
Hachioji-shi, Tokyo 192-0083, Japan
Krakow, Lesser Poland Voivodeship 31-261, Poland
Bialystok, Podlaskie Voivodeship 15-435, Poland
Taipei City, Taipei 11217, Taiwan